Last updated: October 5, 2026
DaTscan, the U.S. brand for ioflupane I-123 injection, is an FDA-approved SPECT imaging agent used to evaluate striatal dopamine-transporter distribution in adults with suspected Parkinsonian syndromes. GE HealthCare owns and markets the product. Its commercial profile is defined by specialized diagnostic demand, nuclear-medicine infrastructure, reimbursement constraints, and limited public financial disclosure.
DaTscan is unlikely to face near-term biosimilar-style erosion. Its principal risks are lower-cost diagnostic substitution, hospital budget pressure, radiopharmaceutical supply logistics, reimbursement changes, and the emergence of competing PET or MRI-based diagnostic approaches. Public filings do not disclose product-level DaTscan revenue, profit, patent expiration, or a dedicated commercial forecast.
What is DaTscan and how is it used?
DaTscan contains ioflupane I-123, a radiolabeled cocaine analog that binds to dopamine transporters in the striatum. The resulting SPECT image helps assess whether presynaptic dopaminergic nerve-terminal density is reduced.
The FDA indication covers adult patients with suspected Parkinsonian syndromes. The label states that DaTscan is an adjunct to other diagnostic evaluations and does not distinguish Parkinson disease from multiple-system atrophy or progressive supranuclear palsy.[1]
| Product attribute |
DaTscan |
| Active ingredient |
Ioflupane I-123 |
| Dosage form |
Intravenous injection |
| Imaging modality |
Single-photon emission computed tomography |
| Therapeutic category |
Diagnostic radiopharmaceutical |
| U.S. approval |
FDA, 2011 |
| U.S. NDA |
022454 |
| U.S. commercial owner |
GE HealthCare |
| Primary use |
Evaluation of suspected Parkinsonian syndromes |
| Administration |
Intravenous injection followed by SPECT imaging |
| Patient population |
Adults |
| Product type |
Small-molecule radiopharmaceutical |
| Biosimilar exposure |
Not applicable |
DaTscan does not treat Parkinson disease. It generates diagnostic information that may help physicians distinguish a dopaminergic deficit from conditions such as essential tremor or drug-induced movement disorders.
What is the FDA regulatory status of DaTscan?
DaTscan received FDA approval in 2011 under NDA 022454. The approval established the product as a diagnostic imaging agent rather than a therapeutic medicine.[1]
The FDA labeling includes important limitations. A normal scan does not exclude all causes of movement disorder, and an abnormal scan does not identify the precise neurodegenerative disease. Interpretation requires visual assessment by qualified readers and correlation with clinical findings.
FDA exclusivity timeline
DaTscan’s likely statutory exclusivity period has expired.
| FDA milestone |
Date or status |
| NDA approval |
2011 |
| Five-year new chemical entity exclusivity |
Likely expired in 2016 |
| Three-year clinical-investigation exclusivity |
Not a current commercial barrier |
| Orphan-drug exclusivity |
Not identified as a governing protection |
| Current regulatory barrier |
Manufacturing, radiopharmaceutical controls, clinical validation, and distribution |
| Current U.S. marketing status |
FDA-approved and marketed |
The FDA-approved label and Drugs@FDA record are the controlling sources for regulatory status. DaTscan’s commercial protection does not appear to depend on active NCE exclusivity.[1]
What patents protect DaTscan?
DaTscan’s core commercial protection is likely weaker than the patent estates surrounding novel therapeutics. The product uses a known diagnostic radioligand, and the public commercial record does not identify a current, high-value U.S. patent barrier comparable to a composition-of-matter patent on a recently approved drug.
Potential protection categories include:
- The chemical composition of ioflupane.
- Radiolabeling and formulation methods.
- Sterile manufacturing processes.
- Kit, vial, or delivery configurations.
- Imaging methods using dopamine-transporter ligands.
- Quality-control and radiopharmaceutical production processes.
The practical value of these categories is uneven. Broad composition claims may be old or expired. Method-of-use claims can be difficult to enforce when physicians use imaging agents for diagnostic purposes. Manufacturing claims can protect production know-how but may not block a technically different supplier.
Are DaTscan patents listed in the Orange Book?
The principal public commercial risk does not appear to come from an active Orange Book patent listing. FDA Orange Book treatment of diagnostic radiopharmaceuticals can differ from conventional oral or injectable therapeutics, and product-specific patent listings should be verified against the current FDA record.[2]
No current, widely reported Orange Book patent dispute has established a clear patent-based exclusion period for DaTscan. The absence of a meaningful listed patent barrier would reduce the relevance of Paragraph IV litigation.
When does DaTscan lose exclusivity?
DaTscan’s principal FDA exclusivity period has already ended. The product is therefore exposed to competition in principle, but regulatory approval alone does not guarantee commercially viable entry.
A competing applicant would need to address:
- Radiochemical synthesis and iodine-123 handling.
- Sterility and endotoxin controls.
- Radioactive decay and shelf-life management.
- Dose calibration and release testing.
- Comparable imaging performance.
- Distribution to nuclear-medicine sites.
- FDA requirements for a diagnostic radiopharmaceutical.
- Reimbursement and hospital purchasing acceptance.
The effective entry barrier is therefore operational and regulatory rather than a clearly identifiable active patent term.
How strong is the DaTscan patent estate?
DaTscan has a moderate-to-weak apparent patent position and a stronger operational position.
| Protection category |
Apparent strength |
Commercial relevance |
| Core molecule |
Low to moderate |
Likely affected by age of underlying chemistry |
| FDA exclusivity |
Low |
Historical exclusivity is expired |
| Formulation |
Moderate if technically differentiated |
Could protect stability and production attributes |
| Method of use |
Low to moderate |
Diagnostic-use claims may be narrow |
| Manufacturing process |
Moderate |
Can create practical entry friction |
| Distribution network |
Moderate to strong |
Radioactive product requires timed delivery |
| Clinical familiarity |
Moderate |
Supports physician and payer acceptance |
| Brand recognition |
Moderate |
Relevant in specialized imaging centers |
The product’s strongest defensible assets are likely its regulatory history, manufacturing controls, physician familiarity, supply chain, and installed imaging-center relationships. These assets can delay or reduce generic uptake even when patent protection is limited.
What generic entry risks exist for DaTscan?
Generic entry risk is real but unlikely to resemble the rapid erosion seen with conventional tablets. An authorized generic or competing ioflupane I-123 product would need to meet demanding operational requirements.
Likely entry scenarios
| Scenario |
Probability profile |
Market effect |
| No direct competitor |
Possible |
GE retains most branded demand |
| One radiopharmaceutical competitor |
Plausible |
Price pressure and account-level switching |
| Multiple suppliers |
Less likely near term |
Material price erosion |
| Hospital-compounded substitute |
Limited |
Quality and regulatory constraints |
| Diagnostic substitution |
Ongoing |
Reduces addressable DaTscan volume |
| Contracting-based discounting |
Likely |
Net price erosion without full generic conversion |
The most credible competitive path is a second FDA-approved radiopharmaceutical with equivalent clinical positioning, not a conventional ANDA-style tablet launch.
Which companies are challenging DaTscan?
No major, publicly reported Paragraph IV challenge or patent litigation campaign against DaTscan was identified through June 2024. The competitive threat comes mainly from diagnostic alternatives and potential future radiopharmaceutical suppliers.
Direct and indirect competitors
Direct competition would include another FDA-approved dopamine-transporter imaging agent using SPECT. In the United States, DaTscan has held a strong position in this narrow category.
Indirect competitors include:
- Clinical diagnosis without molecular imaging.
- Fluorodopa PET in markets where it is available.
- Other investigational dopamine-transporter PET or SPECT agents.
- MRI-based assessments under development.
- Neurologist-directed follow-up without imaging.
- Alternative evaluations for essential tremor and drug-induced parkinsonism.
Reimbursement, scanner availability, and physician confidence determine whether an alternative can displace DaTscan. A technically superior test would still require clinical adoption, payer coverage, and adequate regional distribution.
What is the commercial market for DaTscan?
DaTscan operates in a narrow but durable diagnostic market. Demand is linked to:
- Growth in Parkinson disease evaluation.
- Greater use of objective imaging in uncertain cases.
- Neurology referrals.
- Availability of SPECT cameras.
- Nuclear-pharmacy coverage.
- Payer reimbursement.
- Physician awareness of diagnostic limitations.
The addressable market is smaller than the total Parkinson disease population because DaTscan is generally used when the diagnosis is uncertain, not for routine testing of every patient.
Market advantages
DaTscan has several commercial advantages:
- FDA approval for a defined diagnostic use.
- Longstanding clinical familiarity.
- A recognized brand in movement-disorder imaging.
- Established manufacturing and distribution.
- Use with existing SPECT infrastructure.
- No direct therapeutic substitute for the diagnostic information it provides.
Market constraints
Its growth is limited by:
- High operating complexity relative to ordinary pharmaceuticals.
- Need for a SPECT facility and trained readers.
- Short radioactive half-life and scheduled delivery.
- Reimbursement variation.
- Diagnostic limitations in distinguishing Parkinson disease subtypes.
- Competition from clinical diagnosis and other imaging technologies.
- Hospital pressure to reduce diagnostic costs.
What is DaTscan’s financial trajectory?
GE HealthCare does not publicly report DaTscan revenue, gross margin, prescription volume, or operating profit as a separate business line. The product is included within a broader pharmaceutical diagnostics portfolio.[3]
GE HealthCare reported total 2023 revenue of approximately $19.6 billion, but that figure does not permit a reliable DaTscan revenue calculation.[3] Any product-level estimate based on company segment figures would be speculative.
The most supportable financial assessment is:
| Financial factor |
Assessment |
| Revenue visibility |
Low because GE does not disclose product-level sales |
| Growth profile |
Mature, specialized diagnostic product |
| Price trend |
Exposed to hospital contracting and future supplier competition |
| Volume drivers |
Parkinsonian-syndrome evaluations and SPECT access |
| Margin drivers |
Manufacturing scale, isotope sourcing, distribution efficiency |
| Cost risks |
Radioisotope supply, sterile production, logistics, quality systems |
| Capital intensity |
Moderate at the manufacturing and nuclear-pharmacy level |
| Strategic value |
Portfolio contribution and customer retention rather than blockbuster scale |
| Revenue concentration |
Dependent on a narrow diagnostic indication |
| Forecast confidence |
Limited without company disclosure |
DaTscan’s likely financial trajectory is stable to modestly growing in established markets, with upside from increased diagnostic utilization and downside from reimbursement pressure or competing imaging methods. The product is unlikely to be a major driver of GE HealthCare’s consolidated growth.
What licensing deals affect DaTscan?
GE HealthCare inherited the product through its pharmaceutical diagnostics business, which includes assets developed under the former Amersham and GE Healthcare structure. Public company materials do not identify a current, separately disclosed DaTscan licensing transaction that determines market access.[3]
The commercial model is primarily an integrated manufacturer-distributor model. The product requires coordinated isotope procurement, radiopharmaceutical production, release testing, delivery, and administration. Licensing rights alone would not provide a viable market position without this infrastructure.
What patent litigation and settlement agreements affect DaTscan?
No major publicly reported U.S. patent litigation or Paragraph IV settlement involving DaTscan was identified through June 2024. No settlement agreement is known to establish a delayed generic launch date or a negotiated market-entry date.
The absence of reported litigation is consistent with an older diagnostic product whose competitive barriers are more operational than patent-based. Future disputes could still arise over manufacturing methods, formulation stability, labeling, or diagnostic-use claims, but no such dispute currently defines the product’s commercial outlook.
How does DaTscan compare with competing diagnostic approaches?
| Attribute |
DaTscan SPECT |
Clinical diagnosis |
FDOPA PET |
Emerging PET/MRI approaches |
| FDA-established U.S. use |
Yes |
Yes, as standard care |
Limited availability |
Varies |
| Capital equipment |
SPECT camera |
None beyond clinical setting |
PET scanner |
PET or MRI infrastructure |
| Radiotracer logistics |
Required |
Not required |
Required |
Required |
| Diagnostic information |
Dopamine-transporter distribution |
Clinical phenotype |
Dopaminergic function |
May provide broader biological information |
| Cost profile |
Moderate to high |
Low |
High |
Potentially high |
| Current market access |
Established |
Broad |
More limited |
Developing |
| Direct replacement risk |
Low to moderate |
Moderate |
Moderate |
Long term |
DaTscan’s competitive position is strongest where SPECT infrastructure and reimbursement are established. Its position is weaker where neurologists can make a confident clinical diagnosis without imaging or where PET access is expanding.
What geographic markets matter most for DaTscan?
The United States is commercially important because FDA approval supports broad use across a large neurology and imaging market. European markets also matter because ioflupane SPECT has been used for many years in Parkinsonian-syndrome evaluation.
Geographic performance depends on:
- National reimbursement policy.
- Nuclear-medicine capacity.
- Radiopharmacy density.
- Isotope supply.
- Local diagnostic guidelines.
- Hospital procurement systems.
- Availability of trained readers.
The product’s geographic moat is logistical rather than purely legal. A supplier must deliver a short-lived radioactive product reliably to geographically dispersed imaging centers.
What generic launch scenarios are most likely?
The most likely near-term scenarios are continued GE HealthCare leadership, selective account-level discounting, and gradual substitution by other diagnostic approaches.
A direct generic launch would probably begin in high-volume metropolitan markets with established SPECT infrastructure. A competitor could target hospitals and radiopharmacies through lower pricing, supply guarantees, or contracting terms. National displacement would require broad production capacity and reliable isotope access.
A competing product could gain share without proving superiority if it offers lower net cost, better delivery reliability, or more flexible scheduling. Conversely, DaTscan could retain share despite limited patent protection because diagnostic centers value consistent supply and familiar regulatory documentation.
Key Takeaways
- DaTscan is ioflupane I-123 injection, an FDA-approved SPECT agent for evaluating suspected Parkinsonian syndromes.
- GE HealthCare owns and markets the product.
- FDA approval occurred in 2011, and the principal statutory exclusivity period has expired.
- The commercial moat is based more on manufacturing, isotope logistics, regulatory experience, and clinical familiarity than on a clearly active patent estate.
- No major publicly reported Paragraph IV challenge, patent litigation, or settlement agreement was identified through June 2024.
- GE HealthCare does not disclose DaTscan-specific revenue or profit.
- The product is likely a mature, specialized diagnostic asset with stable to modest growth potential.
- Generic risk is operationally constrained but not eliminated.
- The main long-term threats are competing radiopharmaceuticals, PET-based approaches, clinical diagnosis without imaging, and reimbursement pressure.
- Biosimilar risk does not apply because DaTscan is a small-molecule diagnostic radiopharmaceutical.
FAQs
Is DaTscan a biologic or a small-molecule drug?
DaTscan is a small-molecule radiopharmaceutical containing ioflupane I-123. It is not a biologic and does not face biosimilar competition.
Does DaTscan have an active composition-of-matter patent?
A current, commercially decisive composition-of-matter patent was not identified in the public record reviewed through June 2024. The molecule and diagnostic technology predate the product’s 2011 FDA approval.
Can a hospital use a generic version of DaTscan?
A hospital can use another FDA-approved ioflupane or dopamine-transporter imaging product if one becomes available and is accepted by its formulary and payer. Regulatory approval, supply reliability, and reimbursement would determine practical substitution.
What would most improve DaTscan sales?
Higher use of objective imaging in uncertain Parkinsonian presentations, broader reimbursement, increased SPECT access, and stronger neurologist adoption would support volume growth.
Is DaTscan revenue material to GE HealthCare?
GE HealthCare does not disclose product-level revenue. Based on the company’s diversified scale and DaTscan’s narrow diagnostic indication, the product is unlikely to be material to consolidated revenue, although it can be strategically useful within Pharmaceutical Diagnostics.
References
-
U.S. Food and Drug Administration. (2011). DaTscan (ioflupane I 123 injection) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
GE HealthCare Technologies Inc. (2024). 2023 annual report. GE HealthCare.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: DaTscan, NDA 022454. FDA.
-
European Medicines Agency. (2024). DaTSCAN: EPAR product information. EMA.
